FDA — authorised 11 August 2004
- Marketing authorisation holder: HAMELN PHARMA PLUS
- Status: approved
🇺🇸 Pentetate Calcium Trisodium in United States
FDA authorised Pentetate Calcium Trisodium on 11 August 2004
Marketing authorisations
FDA — authorised 11 August 2004
- Application: NDA021749
- Marketing authorisation holder: HAMELN
- Local brand name: PENTETATE CALCIUM TRISODIUM
- Indication: SOLUTION — INHALATION, INTRAVENOUS
- Status: approved
Pentetate Calcium Trisodium in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Nephrology approved in United States
Frequently asked questions
Is Pentetate Calcium Trisodium approved in United States?
Yes. FDA authorised it on 11 August 2004; FDA authorised it on 11 August 2004.
Who is the marketing authorisation holder for Pentetate Calcium Trisodium in United States?
HAMELN PHARMA PLUS holds the US marketing authorisation.